SAREUM HOLDINGS PLC (“Sareum” or “the Company”) Reference to Potential SRA737 Opportunity in Sierra Oncology Investor Call

On August 6, 2021 Sareum Holdings plc (AIM: SAR), the specialist drug development company, reported that Sierra Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor), held an investor call last night at 10pm BST to discuss its newly announced global in-licensing agreement with AstraZeneca for AZD5153, a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline (Press release, Sareum, AUG 6, 2021, View Source [SID1234586710]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016.

In discussing the rationale for adding AZD5153 to its pipeline, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications, through potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action.

Sierra also noted that AZD5153 had shown preclinical efficacy in combination with a diverse range of agents, and that synergy between AZD5153 and a family of DNA damage response agents, known as ATR inhibitors, suggested potential utility in combination with SRA737.

In its 10-K filing, published yesterday, Sierra reiterated that it is focusing its resources on the development of momelotinib and exploring options to potentially support the continued development of SRA737.

Sareum’s CEO, Dr Tim Mitchell, commented:

"It is encouraging to note from Sierra’s investor call that, while it has made no commitment towards the further development of SRA737, it sees further potential opportunities for this novel agent following the addition of AZD5153 into its pipeline. We remain optimistic that Sierra will find a solution to advance development of the SRA737 programme in the future."